MDSC靶向免疫治疗胰腺癌的研究进展

doi:10.3969/j.issn.1674-8115.2023.10.014

上海交通大学学报（医学版） ›› 2023, Vol. 43 ›› Issue (10): 1317-1323.doi: 10.3969/j.issn.1674-8115.2023.10.014

• 综述 • 上一篇

MDSC靶向免疫治疗胰腺癌的研究进展

秦雅含(), 张珂, 张梦雨, 沈洁, 彭美玉()

潍坊医学院基础医学院山东省高等学校免疫微环境与炎症性疾病研究特色实验室，潍坊 261053

收稿日期:2023-01-19 接受日期:2023-07-07 出版日期:2023-10-28 发布日期:2023-10-28
通讯作者: 彭美玉 E-mail:qyh15689089363@163.com;pmy-107@163.com
作者简介:秦雅含（1998—），女，硕士生；电子信箱：qyh15689089363@163.com。
基金资助:
国家自然科学基金(81972695);山东省高等学校青创人才引育计划“免疫微环境与炎症性疾病研究创新团队”

Research progress of MDSCs-targeted immunotherapy for pancreatic cancer

QIN Yahan(), ZHANG Ke, ZHANG Mengyu, SHEN Jie, PENG Meiyu()

Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, School of Basic Medicine, Weifang Medical University, Weifang 261053, China

Received:2023-01-19 Accepted:2023-07-07 Online:2023-10-28 Published:2023-10-28
Contact: PENG Meiyu E-mail:qyh15689089363@163.com;pmy-107@163.com
Supported by:
National Natural Science Foundation of China(81972695);Shandong Province Higher Education Youth Talent Introduction Program "Immune Microenvironment and Inflammatory Disease Research Innovation Team"

摘要/Abstract

摘要：

胰腺癌（pancreatic cancer，PC）是一种高度恶性的消化系统肿瘤，生存率低且预后较差。大多数胰腺癌患者在疾病早期均无明显临床表现，发现就诊时已处于疾病中晚期。在其发展演变过程中形成了独特且复杂的肿瘤微环境（tumor microenvironment，TME）。由于胰腺癌发病的隐匿性，针对于胰腺癌中晚期患者，仅靠一些传统治疗手段比如手术切除，化疗等显得十分局限，目前缺乏有效的治疗方案。当然，这也与胰腺癌的TME的免疫抑制性有关。一些免疫抑制性细胞，如骨髓源性抑制细胞（myeloid-derived suppressor cells，MDSCs）、调节性T细胞（T-regulatory cells，Treg细胞）等在帮助肿瘤免疫逃逸方面发挥着重要的免疫抑制作用。因此，被认为是治疗胰腺癌的一大难点。近年来，随着对TME的深入研究，免疫治疗也逐渐作为一种新的治疗策略，在多种恶性肿瘤的治疗中取得重大进展。研究发现，靶向MDSC疗法是一种新的且有效的胰腺癌治疗方法。该文就MDSC在TME中发挥的作用及其作为潜在靶点免疫治疗胰腺癌的相关进展进行介绍，以期为胰腺癌等肿瘤的治疗提供新方向。

关键词: 骨髓源性抑制细胞, 胰腺癌, 免疫抑制, 靶向治疗

Abstract:

Pancreatic cancer (PC) is a highly malignant digestive system tumor with a poor survival rate and prognosis. Most patients with pancreatic cancer have no obvious clinical manifestations in the early stage of the disease, and are found to be in the middle and late stage of the disease when they seek treatment.A unique and complex tumor microenvironment (TME) is formed during its development and evolution. Due to the occult nature of pancreatic cancer, for patients with advanced pancreatic cancer, some traditional treatment methods such as surgical resection and chemotherapy are very limited, and there is a lack of effective treatment programs. Of course, this is also related to the immunosuppression of the TME of pancreatic cancer. Some immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), play an important immunosuppressive role in helping tumor immune escape. Therefore, it is considered to be a major difficulty in the treatment of pancreatic cancer. In recent years, with the in-depth study of TME, immunotherapy has gradually become a new therapeutic strategy, and has made great progress in the treatment of various malignant tumors. The study found that targeted MDSCs therapy is a new and effective treatment for pancreatic cancer.In this paper, we introduce the role of MDSCs in TME and their progress as potential targets for immunotherapy of pancreatic cancer, hoping to provide new directions for the treatment of pancreatic cancer and other tumors.

Key words: myeloid-derived suppressor cell (MDSC), pancreatic cancer, immunosuppression, targeted therapy

中图分类号:

R392

秦雅含, 张珂, 张梦雨, 沈洁, 彭美玉. MDSC靶向免疫治疗胰腺癌的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1317-1323.

QIN Yahan, ZHANG Ke, ZHANG Mengyu, SHEN Jie, PENG Meiyu. Research progress of MDSCs-targeted immunotherapy for pancreatic cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1317-1323.

图/表 1

参考文献 58

1	WU J, CAI J T. Dilemma and challenge of immunotherapy for pancreatic cancer[J]. Dig Dis Sci, 2021, 66(2): 359-368.
2	TSUCHIKAWA T, TAKEUCHI S, NAKAMURA T, et al. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer[J]. World J Gastrointest Oncol, 2016, 8(11): 786-792.
3	GILLEN S, SCHUSTER T, MEYER ZUM BÜSCHENFELDE C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4): e1000267.
4	SHARMA V, AGGARWAL A, JACOB J, et al. Myeloid-derived suppressor cells: bridging the gap between inflammation and pancreatic adenocarcinoma[J]. Scand J Immunol, 2021, 93(5): e13021.
5	SARVEPALLI D, RASHID M U, RAHMAN A U, et al. Gemcitabine: a review of chemoresistance in pancreatic cancer[J]. Crit Rev Oncog, 2019, 24(2): 199-212.
6	THYAGARAJAN A, ALSHEHRI M S A, MILLER K L R, et al. Myeloid-derived suppressor cells and pancreatic cancer: implications in novel therapeutic approaches[J]. Cancers, 2019, 11(11): 1627.
7	DYSTHE M, PARIHAR R. Myeloid-derived suppressor cells in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1224: 117-140.
8	KHALED Y S, AMMORI B J, ELKORD E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients[J]. J Immunol Res, 2014, 2014: 879897.
9	GARGETT T, CHRISTO S N, HERCUS T R, et al. GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro[J]. Clin Transl Immunology, 2016, 5(12): e119.
10	NAGARAJ S, GABRILOVICH D I. Tumor escape mechanism governed by myeloid-derived suppressor cells[J]. Cancer Res, 2008, 68(8): 2561-2563.
11	BRONTE V, BRANDAU S, CHEN S H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J]. Nat Commun, 2016, 7: 12150.
12	YOUN J I, NAGARAJ S, COLLAZO M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice[J]. J Immunol, 2008, 181(8): 5791-5802.
13	YOUN J I, GABRILOVICH D I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity[J]. Eur J Immunol, 2010, 40(11): 2969-2975.
14	GABRILOVICH D I, NAGARAJ S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174.
15	PENG M Y, ZHANG Q, LIU Y Q, et al. Apolipoprotein A-I mimetic peptide L-4F suppresses granulocytic-myeloid-derived suppressor cells in mouse pancreatic cancer[J]. Front Pharmacol, 2020, 11: 576.
16	MARVEL D, GABRILOVICH D I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected[J]. J Clin Invest, 2015, 125(9): 3356-3364.
17	OSIPOV A, SAUNG M T, ZHENG L, et al. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape[J]. J Immunother Cancer, 2019, 7(1): 224.
18	PADOAN A, PLEBANI M, BASSO D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity[J]. Int J Mol Sci, 2019, 20(3): 676.
19	APTE M V, XU Z, POTHULA S, et al. Pancreatic cancer: the microenvironment needs attention too![J]. Pancreatology, 2015, 15(4): S32-S38.
20	THAKUR A, SCHALK D, TOMASZEWSKI E, et al. Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway[J]. J Transl Med, 2013, 11: 35.
21	UZUNPARMAK B, SAHIN I H. Pancreatic cancer microenvironment: a current dilemma[J]. Clin Transl Med, 2019, 8(1): 2.
22	POREMBKA M R, MITCHEM J B, BELT B A, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth[J]. Cancer Immunol Immunother, 2012, 61(9): 1373-1385.
23	GABRILOVICH D I, OSTRAND-ROSENBERG S, BRONTE V. Coordinated regulation of myeloid cells by tumours[J]. Nat Rev Immunol, 2012, 12(4): 253-268.
24	LI H Q, HAN Y M, GUO Q L, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1[J]. J Immunol, 2009, 182(1): 240-249.
25	SERAFINI P, MGEBROFF S, NOONAN K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells[J]. Cancer Res, 2008, 68(13): 5439-5449.
26	OSTRAND-ROSENBERG S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity[J]. Cancer Immunol Immunother, 2010, 59(10): 1593-1600.
27	SZEFEL J, DANIELAK A, KRUSZEWSKI W J. Metabolic pathways of L-arginine and therapeutic consequences in tumors[J]. Adv Med Sci, 2019, 64(1): 104-110.
28	RODRÍGUEZ P C, OCHOA A C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives[J]. Immunol Rev, 2008, 222: 180-191.
29	GALLEGO-ORTEGA D, LEDGER A, RODEN D L, et al. ELF₅ drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells[J]. PLoS Biol, 2015, 13(12): e1002330.
30	TALMADGE J E, GABRILOVICH D I. History of myeloid-derived suppressor cells[J]. Nat Rev Cancer, 2013, 13(10): 739-752.
31	BIAN Z, SHI L, VENKATARAMANI M, et al. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice[J]. Eur J Immunol, 2018, 48(3): 532-542.
32	UMANSKY V, BLATTNER C, GEBHARDT C, et al. The role of myeloid-derived suppressor cells (MDSC) in cancer progression[J]. Vaccines, 2016, 4(4): 36.
33	TCYGANOV E, MASTIO J, CHEN E, et al. Plasticity of myeloid-derived suppressor cells in cancer[J]. Curr Opin Immunol, 2018, 51: 76-82.
34	HOLOKAI L, CHAKRABARTI J, LUNDY J, et al. Murine- and human-derived autologous organoid/immune cell co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma[J]. Cancers, 2020, 12(12): 3816.
35	FARAJZADEH VALILOU S, KESHAVARZ-FATHI M, SILVESTRIS N, et al. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer[J]. Cytokine Growth Factor Rev, 2018, 39: 46-61.
36	TADMOR T, ATTIAS D, POLLIACK A. Myeloid-derived suppressor cells: their role in haemato-oncological malignancies and other cancers and possible implications for therapy[J]. Br J Haematol, 2011, 153(5): 557-567.
37	DONG P, YAN Y, FAN Y J, et al. The role of myeloid-derived suppressor cells in the treatment of pancreatic cancer[J]. Technol Cancer Res Treat, 2022, 21: 15330338221142472.
38	HALABY M J, HEZAVEH K, LAMORTE S, et al. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment[J]. Sci Immunol, 2019, 4(42): eaax8189.
39	LAW A M K, VALDES-MORA F, GALLEGO-ORTEGA D. Myeloid-derived suppressor cells as a therapeutic target for cancer[J]. Cells, 2020, 9(3): 561.
40	SUZUKI E, SUN J, KAPOOR V, et al. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects[J]. Cancer Biol Ther, 2007, 6(6): 880-885.
41	SEVKO A, MICHELS T, VROHLINGS M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model[J]. J Immunol, 2013, 190(5): 2464-2471.
42	GHANSAH T, VOHRA N, KINNEY K, et al. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J]. Cancer Immunol Immunother, 2013, 62(6): 1083-1091.
43	MELANI C, SANGALETTI S, BARAZZETTA F M, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma[J]. Cancer Res, 2007, 67(23): 11438-11446.
44	GOEDEGEBUURE P, MITCHEM J B, POREMBKA M R, et al. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer[J]. Curr Cancer Drug Targets, 2011, 11(6): 734-751.
45	ISHERWOOD J, ARSHAD A, CHUNG W Y, et al. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3[J]. Ann Transl Med, 2020, 8(5): 172.
46	GHIRINGHELLI F, APETOH L. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives[J]. Biomed J, 2015, 38(2): 111-116.
47	VINCENT J, MIGNOT G, CHALMIN F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J]. Cancer Res, 2010, 70(8): 3052-3061.
48	ANNELS N E, SHAW V E, GABITASS R F, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer[J]. Cancer Immunol Immunother, 2014, 63(2): 175-183.
49	CONDAMINE T, KUMAR V, RAMACHANDRAN I R, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis[J]. J Clin Invest, 2014, 124(6): 2626-2639.
50	DOMINGUEZ G A, CONDAMINE T, MONY S, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody[J]. Clin Cancer Res, 2017, 23(12): 2942-2950.
51	PENG M Y, HUANG B Q, ZHANG Q, et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells[J]. Cancer Lett, 2014, 354(2): 407-416.
52	GHANSAH T. A novel strategy for modulation of MDSC to enhance cancer immunotherapy[J]. Oncoimmunology, 2012, 1(6): 984-985.
53	VEGLIA F, PEREGO M, GABRILOVICH D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018, 19(2): 108-119.
54	SONG J, LEE J, KIM J, et al. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer[J]. Oncotarget, 2016, 7(32): 51840-51853.
55	NAGARAJ S, YOUN J I, WEBER H, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J]. Clin Cancer Res, 2010, 16(6): 1812-1823.
56	SANCTIS F D, SOLITO S, UGEL S, et al. MDSCs in cancer: conceiving new prognostic and therapeutic targets[J]. Biochim Biophys Acta, 2016, 1865(1): 35-48.
57	FLEMING V, HU X Y, WEBER R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression[J]. Front Immunol, 2018, 9: 398.
58	SANFORD D E, BELT B A, PANNI R Z, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis[J]. Clin Cancer Res, 2013, 19(13): 3404-3415.

[1]	周婉桢, 滕银成. 非经典Wnt通路在卵巢癌中的作用与潜在治疗意义研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1056-1063.
[2]	梅艳青, 韩雨洁, 翁文筠, 张蕾, 唐玉杰. 靶向抑制CDK12/13在高级别胶质瘤中的体外治疗效果和作用分子机制探究[J]. 上海交通大学学报（医学版）, 2023, 43(5): 545-559.
[3]	徐瀛濂, 田静, 张翔, 赵顺英. 气道上皮细胞在哮喘发病机制中的作用研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 619-623.
[4]	魏兰懿, 薛晓川, 陈君君, 杨全军, 王梦月, 韩永龙. 骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 624-630.
[5]	冯琳鸿, 王亚琨, 吴茜茜, 朱迎春, 白寿军. 利妥昔单抗治疗成人难治性原发性膜性肾病的临床分析[J]. 上海交通大学学报（医学版）, 2023, 43(3): 301-307.
[6]	刘铁鑫, 林俊卿, 郑宪友. 靶向亚细胞结构治疗脊髓损伤的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 230-236.
[7]	马芳芳, 秦洁洁, 任灵杰, 唐笑梅, 刘佳, 施敏敏, 蒋玲曦. 基于水凝胶微球建立胰腺癌原代细胞的3D培养模型[J]. 上海交通大学学报（医学版）, 2023, 43(1): 79-87.
[8]	韩永琪, 韩达, 閤谦, 姬丁坤, 谭蔚泓. 核酸适体药物偶联物——肿瘤精准治疗新风向[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1176-1181.
[9]	许静轩, 杜少倩, 曹源, 王红霞, 黄伟翼. MMP14在胰腺癌中的表达及其与肿瘤免疫微环境特征的相关性研究[J]. 上海交通大学学报（医学版）, 2022, 42(3): 312-322.
[10]	李若楠, 陈小科, 许元元, 谭强. ⅠB~ⅢA期非小细胞肺癌患者术后辅助靶向治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1612-1619.
[11]	李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.
[12]	杨鹿笛, 王高明, 胡仁豪, 蒋小华, 崔然. 生物信息学方法筛选胰腺癌进展相关的核心基因[J]. 上海交通大学学报(医学版), 2021, 41(5): 571-578.
[13]	张佳玲, 张凤春, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
[14]	孟爽, 周立, 付勤, 夏立, 孟丽媛. 色谱与质谱参数的优化对免疫抑制剂定量灵敏度的影响[J]. 上海交通大学学报(医学版), 2021, 41(11): 1461-1469.
[15]	李超，糜坚青，王瑾. 费城染色体样急性淋巴细胞白血病的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(9): 1294-1301.

MDSC靶向免疫治疗胰腺癌的研究进展

Research progress of MDSCs-targeted immunotherapy for pancreatic cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 58

相关文章 15

编辑推荐

Metrics